Jamie Blundell brings to Segra over 25 years of experience in senior leadership roles. He has abroad range of B2B and operational expertise with rapidly growing companies in the cannabis, digital media and manufacturing industries. Jamie has previously led operations and business development at corporations that include Yellow Pages and AutoTrader.ca, and most recently acted as President & COO at Cannabis Growth Opportunity Corporation, where he raised $40M in a full prospectus IPO. Through his extensive dealings with M&A, private equity firms, capital markets and large corporate divestitures, he brings a focused and dynamic approach to driving Segra’s growth.
Ian Davidson is a farmer and entrepreneur with more than 15 years of cannabis experience. In 2007, Ian founded Biologic Crop Solutions LLC, which supplies wholesale products and services to over 500 commercial cannabis operations globally. Under Ian’s leadership, BCS established itself as an industry authority on best practices and sustainability for cannabis cultivation. In 2015, Ian founded the agricultural consulting company Davidson Organics, where he developed over 600,000 square feet of high-tech greenhouse cannabis production in California. Ian brings to Segra a career-long dedication to building companies focused on sustainable agricultural production, marketing and distribution.
A recent addition to the Segra team, Sayed brings nine years of progressive public accounting and finance experience. Sayed is a CPA with extensive assurance, tax and financial reporting experience obtained from various roles in public accounting and consulting firms, including KPMG LLP. Prior to joining Segra, Sayed worked with various publicly traded and privately held companies in several industries, including the cannabis industry
Dr. Sma Zobayed is a leading specialist in tissue culturing with extensive international experience. Dr. Zobayed holds two patents relating to tissue culture and has published over 50 scientific papers related to his research in the field. He holds a Ph.D. in Plant Tissue Culture from the Department of Biological Sciences at the University of Hull (UK), and has won awards for his tissue culture work from the scientific community. He is a member in good standing with the International Society of Arboriculture, International Association for Plant Tissue Culture and the International Society for Horticultural Sciences.
Dr. Brunstein is a leading expert on biotechnology, molecular biology, and clinically related topics including clinical trials, assay validation methods and quality systems in regulated industries, with an extensive publication history. He obtained his Ph.D. in Biochemistry from the University of British, working on the molecular biology of viruses, and went on to teach in the Department of Pathology at UBC as Clinical Assistant Professor, where he was recognized with a Faculty Award for Excellence in Research and Discovery and later became the Chief Scientific Officer at the Centre for Translational and Applied Genomics.
Since 1970, David Watson has traveled extensively to cannabis-producing countries looking for seeds of unusual varieties, and in 1975 established Sacred Seeds, the world’s first cannabis seed company, in California. In 1986, he began Cultivator’s Choice, Amsterdam’s first cannabis seed company, breeding and introducing many foundation sinsemilla varieties still grown today. In 1992, Mr. Watson established HortaPharm BV, the world’s first established medical cannabis corporation, and in 1993 he co-founded the International Hemp Association. Working under license from the Dutch Ministry of Health, HortaPharm established facilities used to breed medical cultivars and conduct cannabis research and development. Mr. Watson formulated HortaPharm’s research goals and created the team led by Dr. Etienne De Meijer that was the first to use STS as a breeding method to “self” cannabis plants and create single cannabinoid cultivars. In 1998, HortaPharm supplied varieties along with organic cultivation and integrated pest management expertise to GW Pharmaceuticals in the United Kingdom and assisted in selecting the cultivars used to produce Sativex® and other GW varieties. Mr. Watson co-authored Hemp Diseases and Pests (2000) with John McPartland and Robert Clarke, contributed to Franjo Grotenhermen’s “Cannabis and Cannabinoids” and Mahmoud El Sohly’s “Marijuana and Cannabinoids,” as well as many other articles.